Targeted therapies: Using β-blockers to inhibit breast cancer progression

Nature Reviews Clinical Oncology

Volumn 8, Issue 9, 2011, Pages 511-512

  Powe, Desmond G ^a   Entschladen, Frank ^b  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL; PROPRANOLOL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER MORTALITY; CELL MIGRATION; DISEASE MODEL; DRUG EFFICACY; DRUG USE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER;

ADRENERGIC BETA-ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS;

EID: 80052190882     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.123     Document Type: Article

References (10)

1. Coghill, A. E., Newcomb, P. A. & Potter, J. D. Aspirin use, colorectal cancer survival, and loss to follow-up. JAMA 302, 2549 (2009).
2. Schuller, H. M. Beta-Adrenergic signaling, a novel target for cancer therapy? Oncotarget 1, 466-469 (2010).
3. Algazi, M., Plu-Bureau, G., Flahault, A., Dondon, M.-G. & Le, M. G. Is beta-blocker treatment associated with a decrease in the risk of cancer. Lett. Drug Des. Discov. 3, 653-661 (2006). (Pubitemid 44577159)
4. Bangalore, S. et al. Antihypertensive drugs and risk of cancer: Network meta-Analyses and trial sequential analyses of 324168 participants from randomised trials. Lancet Oncol. 12, 65-82 (2011).
5. Sloan, E. K. et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 70, 7042-7052 (2010).
6. Palm, D. et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int. J. Cancer 118, 2744-2749 (2006). (Pubitemid 43673352)
7. Powe D. et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1, 628-638 (2010).
8. Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K. & Visanathan, K. Beta blockers and breast cancer mortality: A population based study. J. Clin. Oncol. 29, 2635-2644 (2011).
9. Melham-Bertrandt, A. et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J. Clin. Oncol. 29, 2645-2652 (2011).
10. Powe, D. G. et al. Alpha and beta adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: An immunohistochemical study. Breast Cancer Res. Treat. doi:10.1007/s10549-011- 1371-z.